+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

SERCA2 and phospholamban are possible causal genes for hypertrophic cardiomyopathy



SERCA2 and phospholamban are possible causal genes for hypertrophic cardiomyopathy



Circulation 106(19 Suppl.): II-290




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035689029

Download citation: RISBibTeXText


Related references

Microarray analysis of active cardiac remodeling genes in a familial hypertrophic cardiomyopathy mouse model rescued by a phospholamban knockout. Physiological Genomics 45(17): 764-773, 2013

Maximal inhibition of SERCA2 Ca(2+) affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban. Journal of Biological Chemistry 275(16): 12129-12135, 2000

Analysis of 8 sarcomeric candidate genes for feline hypertrophic cardiomyopathy mutations in cats with hypertrophic cardiomyopathy. Journal of Veterinary Internal Medicine 23(4): 840-843, 2009

Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. Biochemical & Biophysical Research Communications 304(1): 1-4, 2003

Decreased cardiac SERCA2 calcium pump activity results in decreased phospholamban protein levels and increased compensatory phosphorylation at phospholamban residues Ser-16 and Thr-17. Circulation 102(18 Suppl.): II 296, 2000

Phospholamban gene mutations are not associated with hypertrophic cardiomyopathy in a Northern Greek population. Biochemical Genetics 43(11-12): 637-642, 2005

Phospholamban gene mutations are not associated with hypertrophic cardiomyopathy in patients from southern Poland. Kardiologia Polska 69(2): 134-137, 2011

Phospholamban ablation rescues cardiac dysfunction in a mouse model of hypertrophic cardiomyopathy. Circulation 102(18 Suppl.): II 218, 2000

The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. Journal of the American College of Cardiology 54(3): 191-200, 2009

Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C>G mutation. European Journal of Heart Failure 9(1): 37-43, 2007

PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing. American Heart Journal 161(1): 165-171, 2011

Differential diagnosis of hypertrophic cardiomyopathies: typical (subaortic) hypertrophic obstructive cardiomyopathy, atypical (mid-ventricular) hypertrophic obstructive cardiomyopathy and hypertrophic non-obstructive cardiomyopathy. European Heart Journal 4 Suppl F: 93, 1983

Phospholamban-to-SERCA2 ratio controls the force-frequency relationship. American Journal of Physiology 276(3 Pt 2): H779-H785, 1999

Increased inhibition of SERCA2 by phospholamban in the type I diabetic heart. Molecular and Cellular Biochemistry 261(1-2): 245-249, 2004

Phospholamban-to-SERCA2 ratio controls the force-frequency relationship. American Journal of Physiology. Heart and Circulatory Physiology 276(3): H779-H785, 2018